Malignant News and Research

RSS

Study shows how PDT for pancreatic cancer can be included in physician practice without significant cost

Late stage pancreatic cancer benefits from photodynamic therapy (PDT) but the resources needed for the usual accompanying dosimetry present barriers, Dartmouth researchers Jonathan T. Elliott, PhD and Brian C. Pogue, PhD have mitigated by using common clinical technologies.

23 Mar 2015

MED15 may serve as prognostic marker for HNSCC recurrence

A new study provides the first evidence that the mediator complex subunit 15 (MED15) may play a crucial role in the pathophysiology of head and neck squamous cell carcinoma (HNSCC). MED15 overexpression was found to be associated with higher mortality rates in HNSCC patients with cancer recurrence, particularly in oral cavity/oropharyngeal tumors, according to the study published in The American Journal of Pathology.

21 Mar 2015

Researchers develop noninvasive method to detect kidney cancer early

If kidney cancer is diagnosed early — before it spreads — 80 percent of patients survive. However, finding it early has been among the disease's greatest challenges.

20 Mar 2015

Researchers successfully generate cells of immune system to target, destroy cancer cells

Researchers at the Max Delbrück Center for Molecular Medicine Berlin-Buch and Charité - Universitätsmedizin Berlin, Campus Berlin-Buch, have succeeded in generating cells of the immune system to specifically target and destroy cancer cells.

20 Mar 2015

New radiation treatment for brain cancer implanted in first human being at CTRC

David Williams is the first human being ever to have a new radiation treatment implanted in the center of his brain tumor.

18 Mar 2015

Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

CTI BioPharma Corp. today announced that results of a Phase 2 study of pacritinib, in patients with myelofibrosis were published in the journal Blood. Pacritinib is a next-generation oral JAK2/FLT3 multikinase inhibitor currently in Phase 3 development in the PERSIST program.

16 Mar 2015

Parenchymal preservation surgery linked to lower mortality, complication rates in cancer patients

A surgical approach in which a surgeon removes less than a lobe of the liver in a patient undergoing an operation for liver cancer is associated with lower mortality and complication rates, according to new study results published online as an "article in press" in the Journal of the American College of Surgeons (JACS).

13 Mar 2015

Slow-growing tumors have treatment-resistant stem cells, shows study

Scientists are eager to make use of stem cells' extraordinary power to transform into nearly any kind of cell, but that ability also is cause for concern in cancer treatment.

12 Mar 2015

AdMeTech Foundation announces launch of statewide prostate cancer awareness program

AdMeTech Foundation today announced the launch of a statewide prostate cancer education and awareness campaign supported by the Massachusetts Department of Public Health.

12 Mar 2015

Oxis Biotech executes licensing agreement with MCIT for development of antibody-drug conjugates

Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. concerning the development of certain antibody-drug conjugates (ADCs).

12 Mar 2015

New method could lead to improved treatment for NPC patients

Researchers at the University of Birmingham believe that a new method of genetically engineering immune cells could lead to improved treatment of Nasopharyngeal carcinoma (NPC) patients.

11 Mar 2015

Study supports use of ThyraMIR, ThyGenX Thyroid Oncogene Panel to improve thyroid cancer diagnosis

PDI, Inc. subsidiary, Interpace Diagnostics, announced today new data supporting the use of combination platform testing with ThyraMIR, the first and only microRNA expression classifier, and ThyGenX Thyroid Oncogene Panel, a DNA and RNA mutational analysis, to improve thyroid cancer diagnosis.

11 Mar 2015

Brain tumor experts launch revolutionary fast-track approach to cancer research

Brain tumor experts at Barrow Neurological Institute at Dignity Health St. Joseph's Hospital and Medical Center have launched a revolutionary fast-track approach to cancer research, giving new hope to brain cancer patients.

10 Mar 2015

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.

10 Mar 2015

MedUni Vienna experts recommend regular colonoscopy screening to prevent bowel cancer

Bowel cancer is one of the most common types of cancer. The prognosis depends greatly on the stage at which the tumour is discovered. Colonoscopy is regarded as the best method for identifying pre-cancerous changes. If these changes are treated promptly, the disease can be stopped in its tracks.

10 Mar 2015

Understanding genetic machinery that drives malignant pediatric adrenocortical tumors

In an advance that could lead to better identification of malignant pediatric adrenocortical tumors, and ultimately to better treatment, researchers have mapped the "genomic landscape" of these rare childhood tumors. Their genomic mapping has revealed unprecedented details, not only of the aberrant genetic and chromosomal changes that drive the cancer, but the sequence of those changes that trigger it.

10 Mar 2015

New ASH report outlines several models for 'systems-based clinical hematologist'

A report released today from the American Society of Hematology in its journal, Blood, presents an innovative, sustainable new role for hematologists, particularly those specializing in non-malignant blood diseases, for today’s rapidly changing U.S. health-care system.

9 Mar 2015

Myriad Publishes myPath™ Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology

Myriad Genetics, Inc. (NASDAQ: MYGN) today announced the Journal of Cutaneous Pathology published data from a pivotal clinical validation study that showed the myPath™ Melanoma test is highly effective at differentiating benign skin moles from malignant melanoma with greater than 90 percent diagnostic accuracy. Melanoma is the most dangerous type of skin cancer and more than 76,000 new cases of melanoma are diagnosed each year in the United States.

6 Mar 2015

CRISPR-Cas9 gene-editing technology targets every gene in the genome in animal cancer model

For the first time, CRISPR-Cas9 gene-editing technology has been employed in a whole organism model to systematically target every gene in the genome.

6 Mar 2015

Majority of asymptomatic, benign thyroid nodules remain benign during follow-up

After five years of follow-up, a majority of asymptomatic, benign thyroid nodules exhibited no significant change in size, or actually decreased in size, and diagnoses of thyroid cancer were rare, according to a study in the March 3 issue of JAMA.

4 Mar 2015

Malignant News and Research

Study shows how PDT for pancreatic cancer can be included in physician practice without significant cost

MED15 may serve as prognostic marker for HNSCC recurrence

Researchers develop noninvasive method to detect kidney cancer early

Researchers successfully generate cells of immune system to target, destroy cancer cells

New radiation treatment for brain cancer implanted in first human being at CTRC

Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

Parenchymal preservation surgery linked to lower mortality, complication rates in cancer patients

Slow-growing tumors have treatment-resistant stem cells, shows study

AdMeTech Foundation announces launch of statewide prostate cancer awareness program

Oxis Biotech executes licensing agreement with MCIT for development of antibody-drug conjugates

New method could lead to improved treatment for NPC patients

Study supports use of ThyraMIR, ThyGenX Thyroid Oncogene Panel to improve thyroid cancer diagnosis

Brain tumor experts launch revolutionary fast-track approach to cancer research

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

MedUni Vienna experts recommend regular colonoscopy screening to prevent bowel cancer

Understanding genetic machinery that drives malignant pediatric adrenocortical tumors

New ASH report outlines several models for 'systems-based clinical hematologist'

Myriad Publishes myPath™ Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology

CRISPR-Cas9 gene-editing technology targets every gene in the genome in animal cancer model

Majority of asymptomatic, benign thyroid nodules remain benign during follow-up

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News